Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos Group's gross profit for the
six
months ended in Dec. 2025 was $585 Mil. Ebos Group's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was $1,116 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Ebos Group's gross profit for the
six
months ended in Dec. 2025 was $585 Mil. Ebos Group's Revenue for the
six
months ended in Dec. 2025 was $4,537 Mil. Therefore, Ebos Group's Gross Margin % for the quarter that ended in Dec. 2025 was 12.91%.
Ebos Group had a gross margin of 12.91% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Ebos Group was 13.35%. The lowest was 9.62%. And the median was 11.46%.
Ebos Group (OTCPK:EBOSY) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ebos Group had a gross margin of 12.91% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Ebos Group Gross Profit Related Terms
Ebos Group Gross Profit Historical Data
* Premium members only.
The historical data trend for Ebos Group's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Gross Profit vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Gross Profit distribution charts can be found below:
* The bar in red indicates where Ebos Group's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,116 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ebos Group (EBOSY) has a Gross Profit of $1,116 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Ebos Group and its competitors.
Is Ebos Group's Gross Profit too high?
Ebos Group's current Gross Profit is $1,116 Mil. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Gross Profit compare to MCK and COR?
Ebos Group's Gross Profit of $1,116 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Distribution company?
A good Gross Profit depends on the Medical Distribution industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Ebos Group and its competitors. Ebos Group's current Gross Profit is $1,116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSY) has a current Gross Profit of $1,116 Mil. The stock's GF Value™ is $47.52, compared to a current price of $26.00 — trading 45.3% below its estimated fair value. The current Gross Profit is $1,116 Mil. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Ebos Group (EBOSY), the current Gross Profit is $1,116 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSY) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $26.00 is trading 45.3% below its estimated GF Value™ of $47.52.
Key valuation signals for EBOSY:
Gross Profit: $1,116 Mil
GF Value™: $47.52 vs. price of $26.00 (45.3% below fair value)
No single metric tells the full story. See the EBOSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSY
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSY has been successfully added to your 
